Humana’s business is heavily Medicare-weighted, which puts Zepbound\u00ae in a tough spot on Part D plans. Medicare Part D does not cover Zepbound for obesity in 2026. CMS has not extended Part D coverage to the obesity indication for tirzepatide, even after the FDA expanded the label.<\/p>\n
The one exception is the OSA indication. The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in December 2024 based on SURMOUNT-OSA, and some Humana Medicare Advantage plans cover Zepbound for OSA when an OSA-related rider is included. This varies by specific plan and state.<\/p>\n
For Humana commercial plans, standard PA criteria apply. The denial reasons cluster around six issues: PA criteria not met, step therapy required, BMI below threshold, employer carve-out, OSA documentation missing, and incomplete weight management program documentation. Each has a documented counter.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Three denial scenarios cover roughly 90 percent of Humana Zepbound rejections.<\/strong> First, the Medicare Part D weight-loss exclusion: Zepbound is not covered for obesity under Part D. Second, on commercial plans, standard PA criteria failures (BMI, lifestyle program, step therapy, employer carve-out). Third, missing polysomnography documentation when applying under the OSA indication.<\/p>\n Quick Answer: Humana Medicare Part D does not cover Zepbound for obesity; the OSA indication is the only viable Medicare pathway<\/p>\n Read your denial letter and find the reason code. Part D denials usually cite the Medicare weight-loss exclusion. Commercial denials cite specific PA criteria failures.<\/p>\n If you have moderate-to-severe OSA with documented AHI of 15 or higher on polysomnography, the OSA indication is the appeal pathway to pivot to. The polysomnography report and AHI documentation are required.<\/p>\n For Humana commercial plans, the 2026 PA criteria for Zepbound require five things: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.<\/strong><\/p>\n Some Humana commercial plans require step therapy with Wegovy\u00ae or an older agent before approving Zepbound. The step requirement can be waived with documented contraindication, intolerance, or insufficient response to the step drug.<\/p>\n For the OSA indication after SURMOUNT-OSA, Humana’s PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 6-month lifestyle program requirement is typically waived under the OSA pathway. For Medicare Advantage plans with an OSA rider, the OSA pathway is the only Zepbound coverage option.<\/p>\n For commercial plans, you have 180 days from the denial date to file a level-1 internal appeal.<\/strong> For Medicare Part D and Medicare Advantage plans, you have 60 days. The submission goes to the address on the denial letter, typically a Humana Pharmacy Appeals address in Louisville, Kentucky.<\/p>\n The appeal packet should include a signed appeal letter from you, a Letter of Medical Necessity signed by your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program (for commercial plans), and prior medication trials. For the OSA pathway, include the polysomnography report with AHI documentation.<\/p>\n Humana has 7 days to respond on a Medicare standard appeal and 72 hours on an expedited Medicare appeal. Commercial appeals get 30 days for standard and 72 hours for expedited.<\/p>\n The LMN is the single most important document.<\/strong> It should be on prescriber letterhead, signed and dated, and limited to two pages.<\/p>\n For commercial plans, hit five points. Current BMI and weight, plus BMI trend over 24 months. Comorbidities with ICD-10 codes. Prior weight-loss interventions with dates and outcomes. Clinical rationale citing SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks, SURMOUNT-2 (Garvey et al. 2023, Lancet) for patients with type 2 diabetes, and SURMOUNT-OSA if applicable. A statement that lifestyle modifications alone have not produced sustained clinical response.<\/p>\n For the OSA pathway on Medicare Advantage, the LMN structure changes. Lead with the OSA diagnosis and AHI from polysomnography. Cite SURMOUNT-OSA directly. State that the request is “for moderate-to-severe OSA per FDA-approved indication based on SURMOUNT-OSA,” not for weight loss.<\/p>\n Humana’s P&T committee references specific trials when updating coverage policy.<\/strong> Citing those trials by name puts your appeal in their internal vocabulary.<\/p>\n For Zepbound in 2026, the strongest references are SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks, SURMOUNT-2 (Garvey et al. 2023, Lancet) showing 15.7 percent weight loss in patients with type 2 diabetes, SURMOUNT-3 (Wadden et al. 2023, Nature Medicine), SURMOUNT-4 for weight maintenance, and SURMOUNT-OSA for the sleep apnea indication.<\/p>\n For Medicare Advantage OSA appeals, SURMOUNT-OSA is the only trial that matters because it is the basis for the FDA’s OSA indication and Medicare coverage of Zepbound for OSA. Lead with SURMOUNT-OSA. SURMOUNT-OSA showed AHI reduction of about 27 events per hour in the treatment arm versus about 4 in placebo.<\/p>\n Key Takeaway: About 38 to 41 percent of Humana denials are overturned at level-1 internal appeal with new documentation (CMS 2023)<\/p>\n For commercial plans, you can file a level-2 internal appeal within 60 days, and pursue external review through your state commissioner in parallel.<\/strong><\/p>\n For Medicare Advantage plans, the next step after level-1 redetermination is independent reconsideration through MAXIMUS (the CMS-contracted Part D IRE). You have 60 days from the level-1 denial to request reconsideration. MAXIMUS has 7 days to respond on standard and 72 hours on expedited.<\/p>\n Beyond MAXIMUS, Medicare appeals continue through an Administrative Law Judge hearing (60 days), Medicare Appeals Council review (60 days), and federal district court (60 days). Most successful Medicare Zepbound appeals are resolved at level-1 or MAXIMUS with proper OSA documentation.<\/p>\n If you have moderate-to-severe obstructive sleep apnea with documented AHI of 15 or higher on polysomnography, the OSA indication is a separate appeal pathway with different criteria.<\/strong><\/p>\n The FDA approved Zepbound for OSA in December 2024 after SURMOUNT-OSA. The LMN should explicitly state “requested for moderate-to-severe OSA per FDA-approved indication based on SURMOUNT-OSA.” Cite the polysomnography results, including AHI and any documented daytime symptoms.<\/p>\n Most Humana commercial plans waive the 6-month lifestyle program requirement under the OSA pathway. Some Humana Medicare Advantage plans cover Zepbound under the OSA indication if the OSA rider is included in the benefit design.<\/p>\n For Humana commercial plans, employer carve-outs of weight-loss drugs cannot be appealed because the benefit comes from the plan document.<\/strong> The OSA indication may be covered separately on some self-funded plans because it is a respiratory disease benefit, not a weight-loss benefit. Ask HR.<\/p>\n For Humana Medicare plans, weight-loss coverage is structurally excluded by CMS for tirzepatide, not by Humana. There is no plan-level carve-out to appeal for obesity. The OSA indication remains the only viable Medicare pathway, and only on plans with the OSA rider.<\/p>\n Cash-pay options include the Eli Lilly LillyDirect direct-cash pharmacy at $349 to $499 per month for Zepbound single-dose vials, and compounded semaglutide through a licensed telehealth platform like TrimRx with a free assessment quiz. Compounded tirzepatide is no longer available through 503A pharmacies after the FDA resolved the tirzepatide shortage in late 2024.<\/p>\n For commercial plans, a standard level-1 internal appeal takes 30 days, level-2 takes 30 days, and external review takes 45 days.<\/strong> Total: 4 to 5 months end to end.<\/p>\n For Medicare Advantage and Part D, level-1 redetermination takes 7 days, MAXIMUS reconsideration takes 7 days, ALJ hearing takes up to 90 days, MAC review takes up to 90 days, and federal court can take a year or more. Most appeals are resolved within a few weeks at level-1 or MAXIMUS.<\/p>\n Expedited appeals on both commercial and Medicare can compress timelines to 72 hours per level when prescribers attest to urgent medical need.<\/p>\n Bottom line: You have 60 days to file a Part D appeal and 180 days for commercial appeals<\/p>\n Possible but rare to succeed. The Letter of Medical Necessity from the prescriber carries clinical authority that a patient letter cannot match. Most prescribers will write one if you ask in writing and provide the denial letter.<\/p>\n Not for obesity, and not for diabetes (since Zepbound is the obesity formulation, not the diabetes formulation). Mounjaro\u00ae is the tirzepatide formulation indicated for type 2 diabetes and is covered under Humana Part D for diabetes with the standard SURPASS-based PA criteria. If you have both diabetes and OSA, Mounjaro covers the diabetes side and Zepbound under the OSA indication may cover the OSA side.<\/p>\n A polysomnography report from a board-certified sleep medicine physician documenting AHI of 15 or higher, the prescriber’s Letter of Medical Necessity citing SURMOUNT-OSA, BMI documentation showing 30 or higher, and any documentation of daytime symptoms (Epworth Sleepiness Scale, motor vehicle accident history, occupational impairment).<\/p>\n Brand-name Zepbound lists at approximately $1,059 per month. The Lilly Savings Card can bring eligible commercially-insured patients to as low as $25 per month for short periods (Medicare patients are not eligible). The LillyDirect direct-cash pharmacy offers Zepbound vials at $349 to $499 per month for cash-pay patients.<\/p>\n Yes, and many patients do when tirzepatide options are limited. Compounded semaglutide from a licensed 503A pharmacy is prescribed through telehealth platforms like TrimRx after a clinical assessment. Costs run roughly $199 to $399 per month depending on dose. Compounded tirzepatide is no longer available through 503A pharmacies as of late 2024.<\/p>\n MAXIMUS is the CMS-contracted independent review entity for Medicare Part D and Medicare Advantage appeals. After your level-1 redetermination is denied by Humana, you have 60 days to request reconsideration by MAXIMUS. MAXIMUS applies CMS coverage criteria directly and operates outside the plan.<\/p>\n Yes. Severe OSA with documented AHI of 30 or higher, daytime sleepiness with motor vehicle accident risk, or evidence of cardiovascular complications all support an expedited appeal request. The prescriber must attest in writing that delay would jeopardize health.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Humana’s business is heavily Medicare-weighted, which puts Zepbound in a tough spot on Part D plans.<\/p>\n","protected":false},"author":11,"featured_media":90052,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"What to Do When Humana Denies Zepbound: Step-by-Step Appeal","_yoast_wpseo_metadesc":"Humana's business is heavily Medicare-weighted, which puts Zepbound in a tough spot on Part D plans.","_yoast_wpseo_focuskw":"humana denies zepbound","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[14],"tags":[],"class_list":["post-90053","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zepbound"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90053"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90053\/revisions"}],"predecessor-version":[{"id":91578,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90053\/revisions\/91578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90052"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Is Humana’s 2026 Prior Authorization for Zepbound?<\/h2>\n
How Do I File a Level-1 Internal Appeal with Humana?<\/h2>\n
What Should the Letter of Medical Necessity Say?<\/h2>\n
What Clinical Evidence Does Humana Respect?<\/h2>\n
What If the First Appeal Is Denied?<\/h2>\n
How Does the OSA Indication Change the Appeal?<\/h2>\n
What If My Humana Plan Carves Out Weight-loss Drugs?<\/h2>\n
How Long Does the Appeal Process Take?<\/h2>\n
FAQ<\/h2>\n
Can I Appeal a Humana Zepbound Denial Without My Doctor’s Help?<\/h3>\n
Does Humana Cover Zepbound for Medicare Patients with Diabetes?<\/h3>\n
What Documents Does Humana Want for the OSA Pathway?<\/h3>\n
How Much Does Zepbound Cost Without Humana Coverage?<\/h3>\n
Can I Switch to Compounded Semaglutide If the Appeal Fails?<\/h3>\n
What Is MAXIMUS and When Do I Use It?<\/h3>\n
Can I Get an Expedited Appeal If I Have Severe OSA?<\/h3>\n